A Study of Guselkumab in Participants With Active Psoriatic Arthritis
This research is investigating a new medication, guselkumab, for individuals living with active psoriatic arthritis, a condition that causes painful and swollen joints, and can also affect the skin. The main goal is to find out how effective guselkumab is at reducing these symptoms and improving overall quality of life, compared to a placebo (a treatment that looks the same but has no active medicine). This is a Phase 3 study, which means it's a later stage of research, usually involving more people, to confirm if the new medicine works and is safe. The study will look at how guselkumab helps with joint pain, swelling, and skin changes caused by psoriatic arthritis.
A colpo d'occhio
Risultati
Risultati di questo studio
Pubblicato February 2026I risultati di questo studio sono stati pubblicati.
Di cosa tratta questo studio?
This study is looking into a new medicine called guselkumab for people who have active psoriatic arthritis. Psoriatic arthritis is a type of arthritis that affects some people who have psoriasis, a skin condition. It can cause joints to become painful, stiff, and swollen, and can also affect other parts of the body like the nails. The goal of this research is to see if guselkumab can help reduce these symptoms and improve a person's quality of life. This is really important because finding effective treatments can make a big difference for people living with psoriatic arthritis.
During the study, some participants will receive guselkumab, while others will receive a 'placebo.' A placebo looks just like the real medicine but contains no active drug. This allows the researchers to fairly compare the effects of guselkumab against no treatment, helping them understand if any improvements are truly due to the new medicine. This kind of study helps scientists gather strong evidence about how well a new treatment works and if it's safe.
The findings from this study will help doctors and patients understand if guselkumab could be a good treatment option for psoriatic arthritis in the future. It's about finding better ways to manage the condition and improve health for those affected by it.
Punti chiave
- This study is testing a new medicine called guselkumab for psoriatic arthritis.
- It aims to see if guselkumab can reduce joint pain, swelling, and other symptoms.
- Some participants will receive the study medicine, others a dummy treatment (placebo).
- You would need to have active psoriatic arthritis that hasn't fully responded to previous treatments.
- Regular health checks and clinic visits would be part of your participation.
- You can stop participating at any time without affecting your normal care.
Chi può essere idoneo?
To join this study, you would need to have active psoriatic arthritis that hasn't fully improved with previous treatments like certain anti-rheumatic drugs, apremilast, or anti-inflammatory medicines. Your doctor would confirm your psoriatic arthritis diagnosis, and you'd need to have specific signs of active disease, such as at least three swollen and three tender joints, and certain levels of a protein called C-reactive protein (CRP) in your blood.
You also need to have at least two joints in your hands or feet showing some damage on X-rays, and your psoriatic arthritis should affect certain types of joints, or you should have active psoriasis on your skin or nails. Participants must be 18 years old or older.
However, you couldn't take part if you have allergies to the study medicine, or if you have other inflammatory conditions like rheumatoid arthritis or lupus, as these might make it hard to tell if guselkumab is working specifically for psoriatic arthritis. You also wouldn't be able to join if you've already had certain types of biologic treatments or specific new medications called JAK inhibitors, or if you've recently taken certain strong medicines that suppress your immune system.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- Hai 18 anni o più?
- Do you have active psoriatic arthritis that other medicines haven't fully helped?
- Do you have at least three swollen and three tender joints?
- Have you NOT previously received certain biologic treatments or specific new medications called JAK inhibitors?
- Do you have active psoriasis on your skin or nails, or certain types of joint involvement?
- Are you able to attend regular clinic visits and follow study instructions?
Cosa comporta la partecipazione?
If you decide to take part in this study, you would receive either the study medicine, guselkumab, or a placebo (a dummy medicine). You wouldn't know which one you're receiving, and neither would your doctor, which helps to keep the study fair. You would have regular visits to the clinic for assessments, which will likely include physical examinations, blood tests, and possibly X-rays, to see how your psoriatic arthritis is responding to the treatment.
These visits are important for monitoring your health and checking for any side effects. You'd be asked to follow specific instructions about taking the study medication. The study will involve a number of visits over a period of time, and the research team will explain the full schedule to you before you agree to participate. They will also keep a close eye on your progress and well-being throughout the entire study.
Rischi e benefici potenziali
Locations (280)
- Rheumatology AssociatesCodice postale verificatoBirmingham, Stati Uniti
- Arizona Arthritis and Rheumatology Research PLLCCodice postale verificatoFlagstaff, United States
- Arizona Arthritis & Rheumatology Associates PCCodice postale verificatoGlendale, Stati Uniti
- Arizona Arthritis & Rheumatology Research, PLLCCodice postale verificatoTucson, Stati Uniti
- Advanced Medical ResearchCodice postale verificatoLa Palma, United States
- Rheumatology Center of San DiegoCodice postale verificatoSan Diego, Stati Uniti
- Medvin Clinical Research, Inc.Codice postale verificatoWhittier, Stati Uniti
- Heuer M.D. ResearchCodice postale verificatoOrlando, Stati Uniti
- The Arthritis Center, Inc.Codice postale verificatoPalm Harbor, United States
- Forcare Clinical Research IncCodice postale verificatoTampa, Stati Uniti
- Klein And Associates M D P ACodice postale verificatoHagerstown, United States
- Advanced RheumatologyCodice postale verificatoOkemos, United States
Domande comuni
Che cos'è il guselkumab?
Guselkumab is a medicine being tested to see if it can help people with psoriatic arthritis by reducing their symptoms.
Che cos'è l'artrite psoriasica?
Psoriatic arthritis is a type of arthritis that causes joint pain, swelling, and stiffness, often affecting people who also have psoriasis, a skin condition.
Che cos'è un placebo?
A placebo is a 'dummy' treatment that looks like the real medicine but contains no active drug. It helps researchers compare the new medicine's effects accurately.
Perché questo studio è importante?
This study aims to find out if guselkumab is an effective and safe treatment for psoriatic arthritis, potentially offering a new option for patients.
Posso lasciare lo studio una volta che mi sono unito?
Yes, you can choose to leave the study at any time, for any reason, and this won't affect your regular medical care.
Come saperne di più
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.